Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets

Mouin G. Seikaly, Pamela G. Waber, Michel Baum

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We recently reported the urinary prostaglandin E2/creatinine ratio (PGE2/Cr) was markedly elevated in Hyp mice, the animal model for X-linked hypophosphatemia, compared with control mice. We provided evidence for altered prostaglandin production mediating the phosphaturia and that indomethacin decreases urinary phosphate excretion in Hyp mice but not control mice. To determine the levels of urinary PGE2/Cr, the safety and efficacy of indomethacin on phosphate excretion in children with hypophosphatemic rickets (HPR), a prospective clinical trial was performed in 16 children with HPR and 16 age- and gender-matched healthy controls. Urinary PGE2/Cr excretion was determined on a 24 h timed urine collection. A randomized cross over, placebo versus indomethacin, clinical trial was performed in the 16 children with HPR. There was no difference in urinary PGE2/Cr excretion between controls and patients with HPR. In children with HPR, indomethacin treatment for 3 mo had no significant effect on serum phosphorus or urinary phosphate excretion. In conclusion, urinary prostaglandin excretion is similar in children with HPR compared with controls. Indomethacin had no significant effect on serum phosphorus or urinary phosphate excretion in children with HPR.

Original languageEnglish (US)
Pages (from-to)210-212
Number of pages3
JournalPediatric Research
Volume64
Issue number2
DOIs
StatePublished - Aug 2008

Fingerprint

Hypophosphatemic Rickets
Indomethacin
Prostaglandins
Phosphates
Dinoprostone
Creatinine
Phosphorus
Familial Hypophosphatemic Rickets
Familial Hypophosphatemia
Clinical Trials
Urine Specimen Collection
Serum
Animal Models
Placebos
Safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets. / Seikaly, Mouin G.; Waber, Pamela G.; Baum, Michel.

In: Pediatric Research, Vol. 64, No. 2, 08.2008, p. 210-212.

Research output: Contribution to journalArticle

@article{7fefa0a971bc4237b8f1b0ac1354baf0,
title = "Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets",
abstract = "We recently reported the urinary prostaglandin E2/creatinine ratio (PGE2/Cr) was markedly elevated in Hyp mice, the animal model for X-linked hypophosphatemia, compared with control mice. We provided evidence for altered prostaglandin production mediating the phosphaturia and that indomethacin decreases urinary phosphate excretion in Hyp mice but not control mice. To determine the levels of urinary PGE2/Cr, the safety and efficacy of indomethacin on phosphate excretion in children with hypophosphatemic rickets (HPR), a prospective clinical trial was performed in 16 children with HPR and 16 age- and gender-matched healthy controls. Urinary PGE2/Cr excretion was determined on a 24 h timed urine collection. A randomized cross over, placebo versus indomethacin, clinical trial was performed in the 16 children with HPR. There was no difference in urinary PGE2/Cr excretion between controls and patients with HPR. In children with HPR, indomethacin treatment for 3 mo had no significant effect on serum phosphorus or urinary phosphate excretion. In conclusion, urinary prostaglandin excretion is similar in children with HPR compared with controls. Indomethacin had no significant effect on serum phosphorus or urinary phosphate excretion in children with HPR.",
author = "Seikaly, {Mouin G.} and Waber, {Pamela G.} and Michel Baum",
year = "2008",
month = "8",
doi = "10.1203/PDR.0b013e318175d788",
language = "English (US)",
volume = "64",
pages = "210--212",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets

AU - Seikaly, Mouin G.

AU - Waber, Pamela G.

AU - Baum, Michel

PY - 2008/8

Y1 - 2008/8

N2 - We recently reported the urinary prostaglandin E2/creatinine ratio (PGE2/Cr) was markedly elevated in Hyp mice, the animal model for X-linked hypophosphatemia, compared with control mice. We provided evidence for altered prostaglandin production mediating the phosphaturia and that indomethacin decreases urinary phosphate excretion in Hyp mice but not control mice. To determine the levels of urinary PGE2/Cr, the safety and efficacy of indomethacin on phosphate excretion in children with hypophosphatemic rickets (HPR), a prospective clinical trial was performed in 16 children with HPR and 16 age- and gender-matched healthy controls. Urinary PGE2/Cr excretion was determined on a 24 h timed urine collection. A randomized cross over, placebo versus indomethacin, clinical trial was performed in the 16 children with HPR. There was no difference in urinary PGE2/Cr excretion between controls and patients with HPR. In children with HPR, indomethacin treatment for 3 mo had no significant effect on serum phosphorus or urinary phosphate excretion. In conclusion, urinary prostaglandin excretion is similar in children with HPR compared with controls. Indomethacin had no significant effect on serum phosphorus or urinary phosphate excretion in children with HPR.

AB - We recently reported the urinary prostaglandin E2/creatinine ratio (PGE2/Cr) was markedly elevated in Hyp mice, the animal model for X-linked hypophosphatemia, compared with control mice. We provided evidence for altered prostaglandin production mediating the phosphaturia and that indomethacin decreases urinary phosphate excretion in Hyp mice but not control mice. To determine the levels of urinary PGE2/Cr, the safety and efficacy of indomethacin on phosphate excretion in children with hypophosphatemic rickets (HPR), a prospective clinical trial was performed in 16 children with HPR and 16 age- and gender-matched healthy controls. Urinary PGE2/Cr excretion was determined on a 24 h timed urine collection. A randomized cross over, placebo versus indomethacin, clinical trial was performed in the 16 children with HPR. There was no difference in urinary PGE2/Cr excretion between controls and patients with HPR. In children with HPR, indomethacin treatment for 3 mo had no significant effect on serum phosphorus or urinary phosphate excretion. In conclusion, urinary prostaglandin excretion is similar in children with HPR compared with controls. Indomethacin had no significant effect on serum phosphorus or urinary phosphate excretion in children with HPR.

UR - http://www.scopus.com/inward/record.url?scp=52649106474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649106474&partnerID=8YFLogxK

U2 - 10.1203/PDR.0b013e318175d788

DO - 10.1203/PDR.0b013e318175d788

M3 - Article

C2 - 18391846

AN - SCOPUS:52649106474

VL - 64

SP - 210

EP - 212

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 2

ER -